Effect of Probiotic Lactobacillus salivarius UBL S22 and Prebiotic Fructo-oligosaccharide on Serum Lipids, Inflammatory Markers, Insulin Sensitivity, and Gut Bacteria in Healthy Young Volunteers: A Randomized Controlled Single-Blind Pilot Study

J Cardiovasc Pharmacol Ther. 2015 May;20(3):289-98. doi: 10.1177/1074248414555004. Epub 2014 Oct 20.


This study investigated the effect of 6-week supplementation of a probiotic strain Lactobacillus salivarius UBL S22 with or without prebiotic fructo-oligosaccharide (FOS) on serum lipid profiles, immune responses, insulin sensitivity, and gut lactobacilli in 45 healthy young individuals. The patients were divided into 3 groups (15/group), that is, placebo, probiotic, and synbiotic. After 6 weeks, a significant reduction (P < .05) in total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides and increase in high-density lipoprotein cholesterol was observed in the probiotic as well as in the synbiotic group when compared to placebo; however, the results of total cholesterol and LDL-cholesterol were more pronounced in the synbiotic group. Similarly, when compared to the placebo group, the serum concentrations of inflammatory markers such as high sensitivity C-reactive protein, interleukin (IL) 6, IL-1β, and tumor necrosis factor α were significantly (P < .05) reduced in both the experimental groups, but again the reduction in the synbiotic group was more pronounced. Also, an increase (P < .05) in the fecal counts of total lactobacilli and a decrease (P < .05) in coliforms and Escherichia coli was observed in both the experimental groups after 6 weeks of ingestion. Overall, the combination of L salivarius with FOS was observed to be more beneficial than L salivarius alone, thereby advocating that such synbiotic combinations could be therapeutically exploited for improved health and quality of life.

Keywords: Lactobacillus salivarius; fructo-oligosaccharides; inflammation; insulin resistance; prebiotics; probiotics; synbiotics.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • C-Reactive Protein / analysis
  • Gastrointestinal Microbiome*
  • Humans
  • Insulin Resistance*
  • Interleukin-6 / blood
  • Lactobacillus*
  • Lipids / blood*
  • Oligosaccharides / pharmacology*
  • Prebiotics*
  • Probiotics / pharmacology*
  • Single-Blind Method
  • Tumor Necrosis Factor-alpha / blood
  • Volunteers


  • Interleukin-6
  • Lipids
  • Oligosaccharides
  • Prebiotics
  • Tumor Necrosis Factor-alpha
  • fructooligosaccharide
  • C-Reactive Protein